Get the Stockscreener App
9.85
0.61%
-0.06
After Hours:
9.80
-0.05
-0.51%
Dyne Therapeutics Inc stock is traded at $9.85, with a volume of 3.49M.
It is down -0.61% in the last 24 hours and up +3.47% over the past month.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
See More
Previous Close:
$9.91
Open:
$9.8
24h Volume:
3.49M
Relative Volume:
1.23
Market Cap:
$1.12B
Revenue:
-
Net Income/Loss:
$-294.51M
P/E Ratio:
-2.7669
EPS:
-3.56
Net Cash Flow:
$-244.42M
1W Performance:
+6.60%
1M Performance:
+3.47%
6M Performance:
-30.73%
1Y Performance:
-77.04%
1-Day Range:
$9.63
$10.04
1-Week Range:
$8.88
$10.23
52-Week Range:
$6.36
$47.45
Dyne Therapeutics Inc Stock (DYN) Company Profile
Name
Dyne Therapeutics Inc
Sector
Industry
Phone
(781) 786-8230
Address
1560 TRAPELO ROAD, WALTHAM
Compare DYN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
9.85 | 1.41B | 0 | -294.51M | -244.42M | -3.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-24-25 | Initiated | Bernstein | Mkt Perform |
| Jun-11-25 | Resumed | Raymond James | Outperform |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-29-25 | Initiated | Evercore ISI | Outperform |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-13-24 | Initiated | Robert W. Baird | Outperform |
| Nov-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-21-24 | Reiterated | Chardan Capital Markets | Buy |
| Apr-30-24 | Initiated | Morgan Stanley | Overweight |
| Feb-20-24 | Initiated | H.C. Wainwright | Buy |
| Feb-27-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Feb-15-23 | Initiated | Oppenheimer | Outperform |
| Jan-26-23 | Initiated | Guggenheim | Buy |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Outperform |
| Oct-12-20 | Initiated | JP Morgan | Overweight |
| Oct-12-20 | Initiated | Jefferies | Buy |
| Oct-12-20 | Initiated | Piper Sandler | Overweight |
| Oct-12-20 | Initiated | Stifel | Buy |
View All
Dyne Therapeutics Inc Stock (DYN) Latest News
Stifel Downgrades Dyne Therapeutics to Buy, Lowers PT to $36. - AInvest
Does Dyne Therapeutics (DYN) Have the Potential to Rally 285.57% as Wall Street Analysts Expect? - Yahoo Finance
Stifel lowers Dyne Therapeutics stock price target to $36 on endpoint changes - Investing.com Canada
Dyne Therapeutics Inc. stock prediction for this weekBuy Signal Based on Chart Analysis Confirmed - metal.it
These Analysts Lower Their Forecasts On Dyne Therapeutics Following Q2 Loss - Benzinga
Dyne Therapeutics Inc. Stock Chart Analysis: Bullish or Bearish Pattern FormingCapital Protection Trading Strategies Gain Interest - metal.it
Can Dyne Deliver And Achieve Milestones In DMD And Myotonic Dystrophy Trials? - RTTNews
How many analysts rate Dyne Therapeutics Inc. as a “Buy”Market Forecast Recommendation With Low Risk - jammulinksnews.com
What is Dyne Therapeutics Inc. company’s growth strategyEntry Signal Signals To Watch Now - jammulinksnews.com
Dyne Therapeutics Advances in Neuromuscular Therapies - TipRanks
Dyne Reports Wider Loss in Fiscal Q2 - The Globe and Mail
Dyne Therapeutics Narrowed Its Loss And Won Analyst Support - Finimize
Dyne Therapeutics: A High-Conviction Biotech Play with Near-Term Catalysts and a Strengthened Balance Sheet - AInvest
Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewswire
Dyne Therapeutics extends cash runway as it advances key drug programs - Investing.com Australia
Dyne Therapeutics, Inc. Q2 Loss Increases, Misses Estimates - Nasdaq
Price Clustering Detected in Dyne Therapeutics Inc. StockWeekly Chart Analysis With Entry Advice Provided - metal.it
Dyne (DYN) Expects Funding to Sustain Operations Through 2027 - GuruFocus
Dyne (DYN) Advances Clinical Programs and Strengthens Financial Position - GuruFocus
Dyne Therapeutics Extends Cash Runway to Q3 2027, Advances Clinical Trials for DM1 and DMD - Quiver Quantitative
Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights | DYN Stock News - GuruFocus
What are analysts’ price targets for Dyne Therapeutics Inc. in the next 12 monthsBuild wealth steadily with smart trading - jammulinksnews.com
What is the dividend policy of Dyne Therapeutics Inc. stockOutstanding capital appreciation - jammulinksnews.com
What is the risk reward ratio of investing in Dyne Therapeutics Inc. stockDiscover breakthrough investment opportunities - jammulinksnews.com
Why is Dyne Therapeutics Inc. stock attracting strong analyst attentionUnlock exclusive trading strategies for gains - jammulinksnews.com
Should I hold or sell Dyne Therapeutics Inc. stock in 2025Breakthrough investment results - jammulinksnews.com
What makes Dyne Therapeutics Inc. stock price move sharplyRecord-setting profit potential - jammulinksnews.com
What are the technical indicators suggesting about Dyne Therapeutics Inc.Track emerging stocks with high growth potential - jammulinksnews.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc.DYN - WV News
Dyne Therapeutics Inc. Stock Analysis and ForecastBreakout profit opportunities - Autocar Professional
What analysts say about Dyne Therapeutics Inc. stockFree Stock Market Return Analysis - Autocar Professional
What drives Dyne Therapeutics Inc. stock priceSuperior risk-adjusted returns - jammulinksnews.com
Is Dyne Therapeutics Inc. a good long term investmentGame-changing returns - Autocar Professional
Dyne Therapeutics Inc Stock (DYN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):